Company Coverage
TA: CITIC (0267 HK) / Innovent Biologics (1801 HK)
Analyst


Analyst
IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS
This report is provided subject to, and must be read together with, the full Disclosures / Disclaimers available at the following link: https://research-api.uobkayhian.com/assets/disclaimer/0e6d602f-adeb-45f8-9dea-5d5591daae87, which are incorporated by reference into this report. In particular, this report is intended for general circulation and informational purposes only and does not constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report. By accessing, receiving or using this report, you acknowledge that you have read, understood and agreed to be bound by the Disclosures / Disclaimers, as may be amended, supplemented or updated from time to time.
Related articles
Our latest research

12 Nov 2026
Hesai Group (2525 HK): 3Q26: Core Earnings Up 16% yoy; Robotics Products Ramping Up
11 Nov 2026
TA: China Tower (0788 HK) / Pop Mart International Group (9992 HK)

9 Nov 2026
